Resolvin E1 reduces hepatic fibrosis in mice with Schistosoma japonicum infection

Qiu,Wenhong; Guo,Kaiwen; Yi,Luyang; Gong,Yeli; Huang,Lixia; Zhong,Wei

doi:10.3892/etm.2014.1641

Resolvin E1 reduces hepatic fibrosis in mice with Schistosoma japonicum infection

Authors:
- Wenhong Qiu
- Kaiwen Guo
- Luyang Yi
- Yeli Gong
- Lixia Huang
- Wei Zhong
View Affiliations

Affiliations: Department of Immunology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China, Department of Immunology, Wuhan University of Science and Technology, Wuhan, Hubei 430080, P.R. China
Published online on: March 27, 2014 https://doi.org/10.3892/etm.2014.1641
Pages: 1481-1485

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate whether resolvin E1 (RvE1) protects against hepatic fibrosis in a murine model of liver fibrosis induced by Schistosoma japonicum infection. A total of 30 pathogen‑free Kunming mice were randomly and equally divided into three groups: Control (uninfected, untreated), model (infected, untreated) and RvE1 intervention (infected, RvE1‑treated; 100 ng daily). The mice were infected with Schistosoma japonicum by inoculating the abdominal skin with 20±2 cercariae to induce models of liver fibrosis. The area and numbers of the granulomas in the livers were assessed through histopathology after 70 days of treatment. The levels of tumor necrosis factor (TNF)‑α and interferon (IFN)‑γ were evaluated in the serum by enzyme‑linked immunosorbent assay (ELISA). The expression levels of TNF‑α were detected in the hepatic tissue by reverse transcription‑polymerase chain reaction and western blot analysis. The activity levels of alanine aminotransferase and aspartate aminotransferase were determined in the serum by ELISA. The expression levels of laminin (LN), hyaluronic acid (HA), procollagen type III (PC‑III) and type IV collagen (IV‑C) were detected in the serum by radioimmunoassays. The results revealed that the mean area of the granulomas was smaller in the RvE1 intervention group compared with that in the model group. Following RvE1 treatment, the serum levels of TNF‑α were lower than those in the model group, while the serum levels of IFN‑γ were higher compared with those in the model group. The expression levels of TNF‑α were lower in the hepatic tissue following RvE1 treatment compared with those in the model group. The indicators of liver fibrosis, the levels of LN, HA, PC‑III and IV‑C in the serum, were lower following RvE1 treatment than those in the model group. In conclusion, RvE1 treatment may reduce the growth of granulomas, thereby slowing the process of hepatic fibrosis, and this effect may be the result of anti‑inflammatory and immune system adjustment.

View Figures

View References

1	Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R and Wynn TA: Immunopathology of schistosomiasis. Immunol Cell Biol. 85:148–154. 2007. View Article : Google Scholar
2	Chitsulo L, Engels D, Montresor A and Savioli L: The global status of schistosomiasis and its control. Acta Trop. 2000.77:41–51
3	Pearce EJ and MacDonald AS: The immunobiology of schistosomiasis. Nat Rev Immunol. 2:499–511. 2002. View Article : Google Scholar : PubMed/NCBI
4	Fabre V, Wu H, PondTor S, Coutinho H, Acosta L, Jiz M, Olveda R, Cheng L, White ES, Jarilla B, McGarvey ST, Friedman JF and Kurtis JD: Tissue inhibitor of matrix-metalloprotease-1 predicts risk of hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis. 203:707–714. 2011. View Article : Google Scholar : PubMed/NCBI
5	Zou WL, Yang Z, Zang YJ, Li DJ, Liang ZP and Shen ZY: Inhibitory effects of prostaglandin E1 on activation of hepatic stellate cells in rabbits with schistosomiasis. Hepatobiliary Pancreat Dis Int. 6:176–181. 2007.PubMed/NCBI
6	Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 117:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE and Serhan CN: Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 285:3451–3461. 2010. View Article : Google Scholar : PubMed/NCBI
8	WHO Expert Committee. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser. 912:2002.PubMed/NCBI
9	Collins C, Xu J and Tang S: Schistosomiasis control and the health system in P.R. China. Infect Dis Poverty. 1:82012. View Article : Google Scholar : PubMed/NCBI
10	Gryseels B, Polman K, Clerinx J and Kestens L: Human schistosomiasis. Lancet. 368:1106–1118. 2006. View Article : Google Scholar : PubMed/NCBI
11	Coutinho HM, Acosta LP, Wu HW, McGarvey ST, Su L, Langdon GC, Jiz MA, Jarilla B, Olveda RM, Friedman JF and Kurtis JD: Th2 cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis. 195:288–295. 2007. View Article : Google Scholar : PubMed/NCBI
12	MacDonald TT: Decoy receptor springs to life and eases fibrosis. Nat Med. 12:13–14. 2006. View Article : Google Scholar : PubMed/NCBI
13	Fichtner-Feigl S, Strober W, Kawakami K, Puri PK and Kitani A: IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 12:99–106. 2006. View Article : Google Scholar : PubMed/NCBI
14	Bonnard P, Remoué F, Schacht AM, Pialoux G and Riveau G: Association between serum cytokine profiles and schistosomiasisrelated hepatic fibrosis: infection by Schistosoma japonicum versus S. mansoni. J Infect Dis. 193:748–750. 2006. View Article : Google Scholar : PubMed/NCBI
15	Henri S, Chevillard C, Mergani A, Paris P, Gaudart J, Camilla C, Dessein H, Montero F, Elwali NE, Saeed OK, Magzoub M and Dessein AJ: Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol. 169:929–936. 2002.PubMed/NCBI
16	Booth M, Mwatha JK, Joseph S, Jones FM, Kadzo H, Ireri E, Kazibwe F, Kemijumbi J, Kariuki C, Kimani G, Ouma JH, Kabatereine NB, Vennervald BJ and Dunne DW: Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol. 172:1295–1303. 2004. View Article : Google Scholar : PubMed/NCBI
17	Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N and Gronert K: Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 192:1197–1204. 2000. View Article : Google Scholar
18	Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G and Moussignac RL: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 196:1025–1037. 2002. View Article : Google Scholar
19	Serhan CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 25:101–137. 2007. View Article : Google Scholar : PubMed/NCBI
20	Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N Jr, Serhan CN and Smith LE: Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 13:868–873. 2007. View Article : Google Scholar : PubMed/NCBI
21	Schwab JM, Chiang N, Arita M and Serhan CN: Nature. 447:869–874. 2007. View Article : Google Scholar